Innovent Biologics' Mazdutide Surpasses Semaglutide In HbA1c And Weight Loss In Phase 3 Trial

Innovent Biologics Inc. (IVBXF, 01801.HK) reported positive Phase 3 DREAMS-3 trial results for its dual GLP-1 and glucagon receptor agonist, mazdutide, in Chinese patients with type 2 diabetes and obesity. The study met its primary endpoint, with 48.0% of mazdutide-treated patients achieving both an HbA1c below 7.0% and at least 10% body weight reduction, significantly outperforming semaglutide's 21.0% (p < 0.0001). Mazdutide also demonstrated superior mean reductions in HbA1c (-2.03% vs -1.84%) and body weight (10.29% vs 6.00%) with a consistent safety profile, positioning it as a potentially superior therapeutic option in a competitive market.

Analysis

Innovent Biologics (01801.HK) has reported highly positive Phase 3 DREAMS-3 trial results for mazdutide, a dual GLP-1 and glucagon receptor agonist, in Chinese patients with type 2 diabetes and obesity. The trial successfully met its primary endpoint, demonstrating superior efficacy compared to semaglutide. Specifically, 48.0% of mazdutide-treated patients achieved both an HbA1c below 7.0% and at least a 10% body weight reduction, significantly outperforming the 21.0% in the semaglutide group (p < 0.0001).

Further efficacy data revealed mazdutide achieved a mean HbA1c reduction of -2.03% versus -1.84% for semaglutide, and a mean body weight reduction of 10.29% compared to 6.00% for semaglutide, with both differences being statistically significant (p < 0.05). The safety profile remained consistent with prior studies, showing no new signals and generally mild to moderate gastrointestinal adverse events.

These results position mazdutide as a potentially next-generation therapeutic option, offering superior combined glycemic control and weight management. The strong statistical significance and comparative outperformance against an established treatment like semaglutide suggest a substantial competitive advantage in the T2D and obesity market, particularly within the Chinese patient population. This positive development reinforces Innovent's product pipeline and future revenue potential.

Key Decisions for Investors

• Investors should closely monitor Innovent Biologics (01801.HK) for regulatory filing timelines and commercialization strategies for mazdutide, given its superior efficacy profile.
• Assess the potential market share capture for mazdutide in the competitive GLP-1 and obesity treatment landscape, particularly within the Chinese market where the trial was conducted.
• Consider the long-term revenue implications for Innovent, as this product could significantly enhance its pipeline and financial outlook, warranting a re-evaluation of current valuations.